OVERVIEW

9th Annual Clinical Cancer Genetics and Genomics Conference is organized by The University of Chicago - Center for Continuing Medical Education and will be held from Apr 17 - 19, 2020.

Target Audience:
This activity is designed for physicians, physician assistants, advanced nurse practitioners, genetic counselors, oncology nurses, and other healthcare professionals currently providing oncology care and cancer genetics risk assessment services or initiating such care and services in their healthcare system. Special efforts will be made to educate clinicians practicing in geographically or socioeconomically underserved communities.

Accreditation:
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 18.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine MOC Part II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

Course Description:
This symposium will render an interdisciplinary educational forum in order to update state-of-the-art science along with the novel therapies for inherited cancers, address real-world cases, curate exceptional pedigrees and plan case summaries to disseminate new knowledge in translational genomics and evidence-based clinical supervision of high-risk subjects and their family members.

Learning Objectives:
At the conclusion of this activity, participants will be able to:
• Recall advanced concepts in genetics, genomics, and next generation sequencing (NGS) technologies;
• Analyze controversies in cancer risk assessment and genetic testing including the integration of polygenic risk scores;
• Recognize how scientific advances in Lynch syndrome and other inherited solid tumors and hematologic malignancies can improve the clinical management of patients;
• Discuss how the integration of novel cancer therapies based on genomic alterations in tumor tissue may reveal germline mutations that can guide patient management;
• Recognize the limitations of genomic testing as it relates to both cancer risk as well as therapeutic selection, including variants of uncertain significance and in silico predictions;
• Identify how a globally-informed perspective on experimental therapeutics for rare cancers including immunotherapy can improve patient outcomes;
• Discuss how emerging concepts in cancer interception and cancer risk modifiers including lifestyle and chemoprevention can impact disease management strategies;
• State the ethical, legal, and social implications of genomic testing in diverse populations.